Erythropoietin response is inadequate in cancer patients receiving chemotherapy

International Journal of Hematology

Volumn 74, Issue 4, 2001, Pages 416-420

  Lee, Sang Jae ^a   Kwon, Jung Hye ^a   Jung, Chul Won ^b  

^a Chung Ang University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Cancer; Ceruloplasmin; Chemotherapy; Cisplatin; Erythropoietin

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANEMIA; ARTICLE; BIOSYNTHESIS; BLOOD; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NEOPLASM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0035747793     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982085     Document Type: Article

References (24)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616-1634.
2. Sawabe Y, Takiguchi Y, Kikuno K, et al. Changes in levels of serum erythropoietin, serum iron and unsaturated iron binding capacity during chemotherapy for lung cancer. Jpn J Clin Oncol. 1998;28: 182-186.
3. Shamseddine A, Khalil A, Seoud M, et al. The relationship between serum levels of erythropoietin (EPO) and insulin-like growth factor-1 (ILGF-1) and hematocrit (HCT) in breast cancer patients receiving non-nephrotoxic chemotherapy. Eur J Gynaecol Oncol. 1998;19:591-593.
4. Cerruti A, Castello G, Balleari E, Bogliolo G, Lerza R, Pannacciulli I. Serum erythropoietin increase in patients receiving adjuvant therapy with 5-fluorouracil and leucovorin. Exp Hematol. 1994;22: 1261-1263.
5. Ray-Coquard I, Le Cesne A, Rubio MT, et al. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol. 1999;17:2840-2846.
6. Canaparo R, Casale F, Muntoni E, et al. Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy. Br J Clin Pharmacol. 2000;50:146-153.
7. Wiltshaw E, Kroner T. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep. 1976;60:55-60.
8. Wood PA, Hrushesky WJM. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995;95:1650-1659.
9. Mukhopadhyay CK, Attieh ZK, Fox PL. Role of ceruloplasmin in cellular iron uptake. Science. 1998;279:714-717.
10. Lee SJ, Jung CW. Roles of red cell distribution width, ferritin, and soluble transferrin receptor as markers for stopping treatment in patients with iron deficiency anemia [abstract]. Kor J Med. 1998; 55(suppl 1):197.
11. Dalton JD, Bailey NP, Barrett-Lee PJ, O'Brien MER. Multicenter UK audit of anemia in patients receiving cytotoxic chemotherapy [abstract]. Proc ASCO. 1998;17:418a.
12. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990;322:16S9-1692.
13. Beguin Y, Yerna M, Loo M, Weber M, Fillet G. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol. 1992;82:648-653.
14. Smith DH, Goldwasser E, Vokes EE. Serum immunoerythropoietin levels in patients with cancer receiving cisplatin-based chemotherapy. Cancer. 1991;68:1101-1105.
15. Urabe A, Mitani K, Yoshinaga K, et al. Serum erythropoietin titers in hematological malignancies and related diseases. Int J Cell Cloning. 1992;10:333-337.
16. Corazza F, Beguin Y, Bergmann P, et al. Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production. Blood. 1998;92: 1793-1798.
17. Hellebostad M, Marstrander J, Slordahl SH, Cotes PM, Refsum HE. Serum immunoreactive erythropoietin in children with acute leukemia at various stages of disease and the effects of treatment. Enr J Haematol. 1990;44:159-164.
18. Beguin Y, Lampertz S, Fillet G. Serum erythropoietin in chronic lymphocytic leukemia. Br J Haematol. 1996;93:154-156.
19. Desoize, B, Berhiot G, Manot L, Coninx P, Dumont P. Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration. Eur J Cancer. 1996;32A:1734-1738.
20. Pivot X, Guardiola E, Etienne M-C, et al. An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia. Eur J Cancer. 2000;36:852-857.
21. Osaki S, Johnson DA. Mobilization of liver iron by ferroxidase (ceruloplasmin). J Biol Chem. 1969;244:5757-5758.
22. Weijl NI, Hopman GD, Wipkink-Bakker A, et al. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann Oncol. 1998;9:1331-1337.
23. Scanni A, Tomirotti M, Licciardello L, et al. Variations in serum copper and ceruloplasmin levels in advanced gastrointestinal cancer treated with polychemotherapy. Tumori. 1979;65:331-338.
24. Cohen Y, Epelbaum R, Haim N, McShan D, Zinder O. The value of serum copper levels in non-Hodgkin's lymphoma. Cancer. 1984;15: 296-300.